Can a Brain Lesion Be a Lymphoma? Primary CNS Lymphoma Explained

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

An MRI shows something in the brain. One mass, deep, lighting up when the contrast goes in. The room starts thinking glioma, or a secondary from a cancer elsewhere. There is a third answer that behaves unlike both, and how the first week is handled decides how fast anyone finds out. A brain lesion is a question before it is a diagnosis, and holding that question open until the evidence closes it is the discipline Healz was built on.

Category
Health Insights
Date
Reading time
11 min
Share

Primary central nervous system lymphoma starts inside the brain, spinal cord, eye or meninges and is found nowhere else in the body. It is often read as something else on the first scan, and it is the one brain lesion where a reasonable treatment decision taken before the biopsy can erase the evidence needed to diagnose it.

Can a Brain Lesion Be a Lymphoma? Primary CNS Lymphoma Explained

Who it happens to

It is uncommon: 3 to 4 percent of intracranial tumours, median age 65 at presentation, rising among older adults for decades (Merck Manual Professional Version). Age carries more than the odds. The NCI PDQ health professional summary states the prognosis is worse for patients 60 years and older, who account for more than half of cases.

There is a second group. PDQ says the disease has increasingly been seen among immunocompromised patients, such as those with HIV, and a US transplant-registry analysis put the risk in solid-organ transplant recipients at roughly 65 times that of the general population (Mahale and colleagues, 2018). In that group the biology differs: PDQ states that immunosuppression-related primary CNS lymphomas are almost always associated with the Epstein-Barr virus. That association belongs to those cases, not to every case.

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

Symptoms follow wherever the mass sits rather than a signature pattern, which is why this is rarely the first suspicion. If the question is still whether a symptom deserves imaging at all, our piece on brain tumour headache red flags covers the features that change the workup.

Why would steroids before a biopsy be a problem?

Corticosteroids such as dexamethasone shrink the swelling around a brain mass fast, and in someone with raised intracranial pressure they relieve symptoms within hours. The trouble is that lymphoma cells are unusually sensitive to them. The Merck Manual Professional Version puts it plainly: because lymphoma is initially highly sensitive to glucocorticoids, these medications should not be given to patients with suspected CNS lymphoma before biopsy, unless acute clinical deterioration requires it, because of the potential for a false negative biopsy.

Physically, the cells the pathologist needs die off and the lesion fades on imaging. Case reports have described this for decades as the "ghost tumour": a lesion clearly present on a scan is absent at surgery, with a long course of corticosteroids in between. A 2026 report in Surgical Neurology International describes steroids inducing rapid apoptosis of lymphoma cells, leading to partial or even complete radiological regression, and notes this reduces the diagnostic yield of biopsy. That is the opposite of what steroids do to a glioblastoma, where volumetric MRI work suggests the apparent shrinkage is mostly vasogenic oedema with the tumour itself roughly unchanged (Cuoco and colleagues, Frontiers in Oncology, 2019). Here it is the cells themselves that die, which is why the cellular morphology a diagnosis rests on gets disrupted.

How large is the effect? A 2024 meta-analysis of 19 studies and 1,226 patients (Tosefsky and colleagues, Neurosurgery, 2024) found patients pretreated with corticosteroids were two times more likely to have a nondiagnostic biopsy, relative risk 2.1. For stereotactic biopsies specifically, the needle procedure that is the usual route to tissue here, they were three times more likely, relative risk 3.0. In the open biopsy subgroup there was no significant difference. The authors concluded that corticosteroids should be withheld, if clinically safe, prior to stereotactic biopsies in suspected primary CNS lymphoma, and that if corticosteroids are given preoperatively, an open biopsy should be considered instead.

Note the condition inside that conclusion: "if clinically safe". Nobody in this literature is saying a person with dangerously raised pressure should be left untreated to protect a specimen. So the action is a question, not a refusal. If lymphoma is on the list, ask whether a biopsy is planned and whether it can happen before steroids are started. If steroids have already been given, which is common and often entirely correct, ask whether an open biopsy is now the better route to tissue. Never decline a drug your own doctor has prescribed for raised intracranial pressure on the strength of an article. Ask about the sequence.

How does it look on MRI next to a glioma or a metastasis?

MRI raises the suspicion. It does not settle it.

Merck says MRI can help differentiate primary CNS lymphoma from other intracranial pathology based on T2-weighted hyperintensity, diffuse contrast enhancement and diffusion restriction, and that lymphomas tend to infiltrate the brain diffusely, often as multicentric masses adjacent to the ventricles, but may occur as solitary masses. PDQ adds that homogenous enhancement is almost always seen in patients without HIV, a condition that belongs with the claim.

Against a glioblastoma, the useful difference is the texture of the enhancement. A single-centre comparison of 21 patients with primary CNS lymphoma and 13 with glioblastoma, by Xiang and colleagues in the Iranian Journal of Radiology in 2019, found homogeneous enhancement in 95.2 percent of the lymphomas while all the glioblastomas enhanced heterogeneously. Necrotic or cystic components appeared in 11 of 13 glioblastomas and in one lymphoma. That is 34 patients in one centre, so read it as a pattern supporting a suspicion, not a rule deciding a case. If glioma is the working diagnosis instead, the molecular lines matter more than the grade above them, which we walk through in what IDH status changes on a brain tumour report.

Against a metastasis, the distinction is largely settled outside the head. PDQ states that PET-CT scans are used to exclude occult systemic disease of the chest, abdomen and pelvis. Merck adds that 18-FDG PET is used to differentiate primary CNS lymphoma from systemic lymphoma seeding the brain secondarily, a different disease with a different plan.

What the spinal fluid and the eye examination are for

The workup looks wider than one lesion would suggest. PDQ is explicit that all compartments of the CNS should be evaluated, even if asymptomatic, including the vitreoretinal compartment and the cerebrospinal fluid when feasible.

Writing in the American Society of Hematology Education Program in 2016, Tracy Batchelor describes CSF assessed by flow cytometry, cytology and immunoglobulin heavy-chain gene rearrangement, and reports secondary CSF involvement in roughly 15 to 20 percent of patients. Merck notes CSF must be examined to exclude lymphomatous meningitis when there is gadolinium enhancement on MRI or meningeal signs on examination, especially if cranial neuropathies are present, and that Epstein-Barr virus DNA may be found in it. A clean tap does not close the question: Merck states that if the CSF contains no lymphoma cells and no Epstein-Barr virus DNA, a guided-needle or open biopsy is required.

The eye examination surprises people. Batchelor recommends a comprehensive eye evaluation by an ophthalmologist including a slit-lamp examination, to look for involvement of the optic nerve, retina or vitreous, and reports ocular involvement in roughly 5 to 20 percent of patients. Merck lists slit-lamp examination in the staging workup alongside imaging of the chest, abdomen and pelvis and a bone marrow biopsy, which PDQ notes may be excluded with a clear PET-CT scan. An eye appointment for what looks like a brain problem is not an administrative error. It is one of the compartments.

Why it is treated by a different route from other brain tumours

With most brain tumours the first conversation is how much can be taken out. Here it is not.

Batchelor states that surgical resection is not part of the standard treatment approach, given the multifocal nature of the tumour, and that neurosurgery's role is mainly stereotactic biopsy for diagnosis. Merck is blunter: there is no role for surgical excision except when herniation is impending. The operation exists to get tissue, which is exactly why the steroid question carries so much weight. If the one operation whose job is to produce a diagnosis comes back undiagnostic, there is no debulking consolation prize, only a delay and a second attempt.

Treatment is drug-led and has to reach the whole central nervous system. PDQ states that outside of clinical trials, high-dose methotrexate is the most frequently used standard induction therapy, and Batchelor notes that doses of at least 3 g/m2 achieve therapeutic levels in brain parenchyma and CSF. Radiation has moved: PDQ notes the significant neurotoxicity of standard-dose whole-brain radiation therapy has reduced its role, and Merck warns it can cause clinically significant leukoencephalopathy, particularly in older patients, an effect that may be exacerbated by methotrexate.

What Healz does with a brain lesion workup

Everything about this case lives in one chat, not across ten apps. What makes that work is what sits in the one place.

Frontier AI reads the radiology report in full context, so the enhancement pattern, the location and the diffusion finding are read together instead of as separate lines. Healz is equipped with root-cause technology, so it does not accept the first label: it cross-references your case against 1M+ rare cases, names the mimics that belong on the differential for this lesion, and surfaces the question that decides between them, which here is whether tissue is planned before steroids. Healz's memory holds every report and scan you upload, dated, so the pre-steroid scan and the post-steroid scan stay side by side instead of the second one quietly becoming the record.

That is worth doing before a procedure rather than after it: not a second opinion and not a different answer, but a check on whether the right question is being asked while it can still be answered. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

Can a brain lesion turn out to be a lymphoma?

Yes. Primary CNS lymphoma begins in the brain, spinal cord, eye or meninges and is found nowhere else. It accounts for 3 to 4 percent of intracranial tumours, median age at presentation 65 (Merck Manual Professional Version), and is commonly read as a glioma or a metastasis on the first scan.

Should I refuse steroids if a brain lymphoma is suspected?

No. The guidance is about sequence, not refusal, and every source states the exception. Merck says glucocorticoids should not be given before biopsy in suspected CNS lymphoma unless acute clinical deterioration requires it. Ask whether a biopsy is planned and whether it can happen first, and never stop a drug prescribed for raised intracranial pressure on your own.

Can steroids make a brain tumour disappear on MRI?

With lymphoma, at least partly, yes. A 2026 report in Surgical Neurology International describes steroids causing rapid death of lymphoma cells with partial or even complete radiological regression, long known in case reports as the ghost tumour effect, and notes that this reduces the diagnostic yield of biopsy.

Does a negative spinal tap rule out CNS lymphoma?

No. Merck states that if the CSF contains no lymphoma cells and no Epstein-Barr virus DNA, a guided-needle or open biopsy is required. Secondary CSF involvement occurs in roughly 15 to 20 percent of patients (Batchelor, ASH Education Program 2016), so the tap finds disease in that compartment rather than excluding the diagnosis.

What happens if the biopsy comes back undiagnostic?

The diagnosis waits, and so does treatment. The 2024 meta-analysis found no significant difference in nondiagnostic rates for open biopsy, so where steroids have already been given, the authors suggest considering an open biopsy rather than a stereotactic one.

A brain lesion is a hypothesis, and Healz was built to keep testing it until the evidence, not the first label, closes the question.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health